Study Details

Back to Search Results

A Multiple Dose Escalation Study of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01585233

Astellas Study ID

The unique identification code given by the study sponsor.

7163-CL-0107

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Psoriasis

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - 75 Years

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2012 - Jan 2015

Masking

Double (Participant, Investigator)

Enrollment number

60

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Multiple Dose Escalation Study of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Specialist Connect

Brisbane, Australia, 4102

CMAX

Adelaide, Australia, 5000

Epworth Hospital

Richmond, Australia, 3121

Linear Research

Nedlands, Australia, 6009

Winnipeg Clinic

Winnipeg, Canada, R3C 0N2

Durondel C.P. Inc, The Dermatology Clinic

Moncton, Canada, E1C 8X3

New Lab Clinical Research

St. John's, Canada, A1C 2H5

Ultranova Skincare

Barrie, Canada, L4M 6L2

K. Papp Clinical Research

Waterloo, Canada, N2J 1C4

Innovaderm Research, Inc.

Montreal, Canada, H2K 4L5

Auckland Clinical Studies

Auckland, New Zealand, 1010

Christchurch Clincial Studies Trust, Ltd.

Christchurch, New Zealand, 8011

P3 Research, Tauranga

Tauranga, New Zealand, 3110

P3 Research, Wellington

Wellington, New Zealand, 6021

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo